New compound ASG-5ME uses a monoclonal antibody against target found in more than 90% of pancreatic cancer patients - EurekaAlert! (article link)

ASG-5ME is a potent, targeted compound designed to selectively kill cancer cells, -- "ASG-5ME is intended for pancreatic cancer patients who do not have a good prognosis with currently available therapies. We are very pleased to be able to offer this exciting agent in a clinical trial for patients with advanced pancreatic cancer,"

- The new investigational compound uses a monoclonal antibody against a target which is found in more than 90% of pancreatic cancer patients.
- The monoclonal antibody delivers a highly potent molecule called monomethyl auristatin E (MMAE) to selectively kill the pancreatic cancer cells.